Puma Biotechnology Inc (PBYI)

5.270
-0.420(-7.38%)
After Hours
5.280
+0.010(+0.19%)
- Real-time Data
  • Volume:
    1,075,898
  • Bid/Ask:
    5.110/5.280
  • Day's Range:
    4.920 - 5.830

PBYI Overview

Prev. Close
5.69
Day's Range
4.92-5.83
Revenue
254.86M
Open
5.69
52 wk Range
4.92-14.14
EPS
-0.89
Volume
1,075,898
Market Cap
214.91M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
422,908
P/E Ratio
-
Beta
0.95
1-Year Change
-44.53%
Shares Outstanding
40,779,030
Next Earnings Date
Nov 04, 2021
What is your sentiment on Puma Biotechnology Inc?
or
Market is currently closed. Voting is open during market hours.

Puma Biotechnology Inc News

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesSellSellStrong SellStrong SellStrong Sell
Technical IndicatorsStrong BuyStrong SellStrong SellStrong SellStrong Sell
SummaryNeutralStrong SellStrong SellStrong SellStrong Sell

Puma Biotechnology Inc Company Profile

Puma Biotechnology Inc Company Profile

Employees
267

Puma Biotechnology, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of products to improve cancer care. The Company's products include PB272 (neratinib, oral), PB272 (neratinib, intravenous), and PB357, as well as certain related compounds. Its lead product, NERLYNX, is an oral version of neratinib, which is a potent irreversible tyrosine kinase inhibitor (TKI), that blocks signal transduction through the human epidermal growth factor receptors, HER1, HER2 and HER4. Its initial focus is on the development of neratinib as an oral treatment for patients with HER2-positive metastatic breast cancer. Its product candidate, PB357, is an orally administered agent that is an irreversible TKI that blocks signal transduction through the epidermal growth factor receptors. The Company has two subsidiaries: Puma Biotechnology Ltd and Puma Biotechnology, B.V.

Read More
  • Puma Biotechnology Q1 Adj. EPS $(0.200) Beats $(0.730) Estimate, Sales $48.600M Beat $47.060M Estimate
    0
    • 14,5 short
      0
      • today will be earnings as All eyes will be on the Useless CEO
        0
        • Leerink set PT to $115. Wonder if they think there is no immediate buyer?
          0
          • $PBYI will be presenting at ASCO on 6/3/17. Buy the stock now... This can go above $100 easily before the event
            0
            Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
            Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.